US20230108852A1 - Controlled release system for pulmonary delivery of surfactant protein d - Google Patents
Controlled release system for pulmonary delivery of surfactant protein d Download PDFInfo
- Publication number
- US20230108852A1 US20230108852A1 US17/752,418 US202217752418A US2023108852A1 US 20230108852 A1 US20230108852 A1 US 20230108852A1 US 202217752418 A US202217752418 A US 202217752418A US 2023108852 A1 US2023108852 A1 US 2023108852A1
- Authority
- US
- United States
- Prior art keywords
- spd
- plga
- nps
- disease
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 title claims abstract description 134
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 title claims abstract description 134
- 238000013270 controlled release Methods 0.000 title claims abstract description 16
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 8
- 239000002105 nanoparticle Substances 0.000 claims abstract description 102
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 230000003247 decreasing effect Effects 0.000 claims abstract description 12
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 210000004072 lung Anatomy 0.000 claims description 17
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 229920000954 Polyglycolide Polymers 0.000 claims description 5
- 239000004633 polyglycolic acid Substances 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 3
- 230000002085 persistent effect Effects 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 2
- 208000032376 Lung infection Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- -1 poly-alkyl cyanoacrylates Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 15
- 241000699670 Mus sp. Species 0.000 description 29
- 239000002245 particle Substances 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 230000037396 body weight Effects 0.000 description 13
- 238000002296 dynamic light scattering Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000011813 knockout mouse model Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101000632467 Homo sapiens Pulmonary surfactant-associated protein D Proteins 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000010398 acute inflammatory response Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical class O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010058490 Hyperoxia Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000000222 hyperoxic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000018773 low birth weight Diseases 0.000 description 2
- 231100000533 low birth weight Toxicity 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 101150078806 BCAT2 gene Proteins 0.000 description 1
- 102100026413 Branched-chain-amino-acid aminotransferase, mitochondrial Human genes 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010006472 Escherichia coli ribosome-associated protein SRA Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010024825 Loose associations Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000001198 high resolution scanning electron microscopy Methods 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 201000009621 pulmonary immaturity Diseases 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present invention relates to a controlled release system for administration of surfactant protein D for treating lung disease.
- Preterm infants particularly those of very low birth weight that were born between week 23 and week 28 of gestation, suffer from a very high incidence of respiratory distress syndrome (RDS) related to pulmonary immaturity and inability to make pulmonary surfactant lipids and proteins.
- RDS respiratory distress syndrome
- the surfactant replacement preparations currently at use contain surfactant protein (SP) B and SPC but do not contain SPA, SPD, or other innate host-defense proteins (Ikegami et al. 2006; WO 90/11768).
- SPD is a hydrophilic surfactant protein that decreases pulmonary inflammation and facilitates normal surfactant lipid structure and recycling.
- the present invention provides a controlled release system comprising surfactant protein D (SPD) and a carrier suitable for controlled release.
- SPD surfactant protein D
- the present invention provides a nanoparticle comprising SPD and PLGA.
- the present invention provides a pharmaceutical composition comprising the controlled release system or nanoparticle according to the invention.
- the present invention provides a method of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, comprising administering the system or nanoparticle according to the invention or a pharmaceutical composition thereof to said subject.
- the present invention provides a method for pulmonary delivery of SPD comprising administering to a subject in need thereof the system or nanoparticle according to the invention or a pharmaceutical composition thereof.
- FIGS. 1 A- 1 D show scanning Electron Microscopy (SEM) images of poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) with surfactant protein D (SPD).
- FIGS. 1 A and 1 B PLGA 1A NPs with SPD;
- FIGS. 1 C and 1 D PLGA 7A NPs with SPD.
- FIGS. 1 A and 1 C are at ⁇ 10,000 magnification
- FIGS. 1 B and 1 D are at ⁇ 35,000 magnification.
- FIG. 2 shows hydrodynamic radius of PLGA NPs with SPD in PBS solution measured with Dynamic Light Scattering (DLS). From left to right: PLGA-7A, PLGA-7A with SPD, PLGA-1A, PLGA-1A with SPD.
- DLS Dynamic Light Scattering
- FIG. 4 shows Zeta potential of PLGA 1A and 7A NPs with and without SPD in PBS solution. From left to right: PLGA 1A, PLGA 7A, PLGA 7A with SPD.
- FIG. 5 shows toxicity test of C57b1/6 mice by intra-tracheal injection of PLGA 7A empty NPs at 10 and 20 ⁇ g particles per gram body weight, 2 or 4 weeks after the 8 injection.
- Control group was injected with 100 ⁇ l sterile PBS and tested after 2 weeks.
- FIG. 6 shows SDS-PAGE analysis of SPD released from NPs during one week.
- First four lanes from the left include different concentrations of SPD (left to right: 25, 50, 100 and 200 ⁇ g/ml), next two lanes include washes, and the following lanes include daily samples from day 0 to day 7.
- the right-most lane is sample taken at day 1 without ⁇ -ME (normally added to each sample to keep a denatured state).
- 40 kD marks the approximate location of the SPD monomer (43 kDa)
- 120 kD marks the approximate location of the SPD trimer (129 kDa).
- FIG. 7 shows biological activity of SPD protein that was released from PLGA 1A NPs during one week using bacterial aggregation assay.
- PBS blue diamond
- wash red square
- Day 0 green triangle
- Day 1 purple X
- Day 2 blue asterisk
- Day 3 orange circle
- Day 4 perpendicular bar
- Day 5 brown line
- Day 6 green line
- Day 7 purple diamond.
- BALF Bronchiolar Lavage Fluid
- FIG. 10 shows SP-D concentration measured by human SP-D ELISA, in bronchial lung lavage supernatant from knock-out mice after intra-tracheal injection of PLGA 7A NPs with SP-D at 20 ⁇ g per gram body weight (left bars), or of empty PLGA 7A NPs (middle bars).
- PLGA poly lactic-co-glycolic acid
- SPD surfactant protein D
- Poly(lactic-co-glycolic acid) is a biodegradable and biocompatible FDA-approved copolymer used as a vehicle for delivery, including controlled delivery of drugs.
- PLGA is synthesized by means of ring-opening co-polymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid.
- Polymers can be synthesized as either random or block copolymers thereby imparting additional polymer properties.
- successive monomeric units (of glycolic or lactic acid) are linked together in PLGA by ester linkages, thus yielding linear, aliphatic polyester as a product.
- PLGA 75:25 identifies a copolymer whose composition is 75% lactic acid and 25% glycolic acid).
- Additional carriers may be used in accordance with the present invention instead of PLGA, including polymeric carriers such as polylactic acid (PLA), polyglycolic acid (PGA), chitosan, gelatin, polycaprolactone and poly-alkyl-cyanoacrylates (Kumari et al, 2010).
- the carrier is biodegradable.
- Examples 1-3 show that PLGA and SPD form complexes having the size of nanoparticles.
- Example 5 further demonstrates that SPD protein continues to he released from these nanoparticles for a duration of at least a week, and
- Example 6 shows that the released SPD is biologically active.
- Examples 9 and 10 show that SPD is released from the SPD NPs of the invention after administration to lungs of wild-type or knock-out mice.
- the present invention provides a controlled release system comprising SPD and a carrier suitable for controlled release.
- the carrier of the system/nanoparticle is polymeric, i.e. comprising a polymer.
- the carrier is PLGA.
- complex refers to a molecular entity formed by loose association involving two or more component molecular entities (ionic or uncharged), or the corresponding chemical species; and this term and the term “system” are used herein interchangeably.
- the ratio of lactic acid to glycolic acid in the PLGA polymer of the system/nanoparticle may vary.
- the ratio which was used in the experiments of the present invention is 50:50. However, other ratios may also be suitable as indicated below.
- the ratio of lactic acid to glycolic acid in said PLGA is 50:50, 65:35, 70:30, 75:25, 82:18 or 85:15, in particular the ratio is 50:50.
- the polymer may be at any of various inherent viscosities between 0.05 and 7.0 dL/g, for example 0.05 to 1 dl/g or between 0.1 to 0.7 dl/g (depending on the molecular weight, molecular weight distribution, and consistency of the polymer).
- the molecular weight of the PLGA may be selected from between 1 to 200, between 3 to 150 or between 5 to 100 kDa.
- two types of PLGA polymers were used, with molecular weights of 96 kDa and (inherent viscosity of 0.63 dl/g) and 5.6 kDa (and inherent viscosity of 0.11 dl/g).
- the radius of the nanoparticles is about 100 nm. Accordingly, in some embodiments, the system is a nanoparticle or a microparticle, in particular a nanoparticle. In some embodiments, the average radius of said nanoparticle is selected from between 20 and 300, between 50 and 150 nm, or about 100 nm.
- the zeta potential affects the tendency of the particles to aggregate; charged particles have a lesser tendency to aggregate due to the repulsing forces of particles having the same charge, while neutrally charged particles have a tendency to aggregate. There is therefore an advantage to particles having a charge.
- the SPD-loaded PLGA nanoparticles disclosed in herein have a negative zeta potential of about ⁇ 35 mV (Example 3).
- the present invention provides a nanoparticle comprising SPD and PLGA.
- the SPD was prepared as previously described (Ikegami et al., 2006).
- the SPD may be recombinant SPD.
- the SPD is a mammalian SPD, in particular human SPD.
- the system does not contain surfactant components other than SPD.
- the system comprises SPD but is void of SPA, SPB or SPC.
- controlled release is used herein interchangeably with the terms “prolonged-action”, “repeat-action”, “extended release”, and “sustained-release” and refers to the release of an active agent at predetermined intervals or gradually, in such a manner as to make the contained active agent available over an extended period of time
- the system of the invention as described hereinabove is for use in pulmonary delivery of SPD, i.e. for use in delivery of SPD to the lungs.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the system/complex/nanoparticle of the invention as described hereinabove and a pharmaceutically acceptable carrier.
- compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active agents into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- the pharmaceutical composition may be aerosolized by any known method such as by a pneumatic, jet or ultrasonic nebulizer. Methods and devices for aerosolization are described, for example, in Labiris and Dolovich 2003, Br. J. Clin. Pharmacol. 56: 600-612, and in (2004) et al., 2015, Medical Devices: Evidence and Research 8: 131-139.
- the pharmaceutical composition is in the form of an aerosol, spray or mist.
- pharmaceutically acceptable carrier refers to a vehicle which delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms.
- pharmaceutical will be understood to encompass both human and veterinary pharmaceuticals.
- Useful carriers include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1, 3-diol, isopropyl myristate, isopropyl palmitate, mineral oil and polymers composed of chemical substances like polyglycolic acid or polyhydroxybutyrate or natural polymers like collagen, fibrin or polysaccharides like chitosan and alginate.
- the carrier may be in any form appropriate to the mode of delivery, for example, solutions, colloidal dispersions, emulsions (oil-in-water or water-in-oil), suspensions, gels, sprays and the like.
- bronchoalveolar SPD refers to partial or complete deficiency of bronchoalveolar SPD as compared with the level of bronchoalveolar SPD in normal healthy individual(s). It has been shown for several diseases, including acute respiratory distress syndrome (ARDS) and respiratory syncytial virus (RSV) that the levels of SPD, even if they are within the normal range, correlate with mortality rates or with disease outcome. Accordingly, the term “decreased levels of bronchoalveolar SPD” may be also used to further refer to a decreased level of bronchoalveolar SPD which is still within the normal range but is associated with poor prognosis of a disease.
- ARDS acute respiratory distress syndrome
- RSV respiratory syncytial virus
- Non-limiting examples of individuals having decreased levels of bronchoalveolar SPD include preterm infants, particularly those of very low birth weight that were born between about week 23 and about week 28 of gestation, and individuals with a mutated spd gene resulting in reduced expression or altered activity.
- the disease, disorder or condition is selected from chronic obstructive lung disease (COPD), asthma, acute bronchitis, chronic bronchitis, bronchopulmonary dysplasia, emphysema, infant respiratory distress syndrome (IRDS), acute respiratory distress syndrome (ARDS), lung infections, persistent pulmonary hypertension, lung hypoplasia, cancer, cystic fibrosis, alveolar proteinosis, upper respiratory inflammation, congenital SP-B deficiency, respiratory syncytial virus (RSV), allergic rhinitis, and/or influenza.
- COPD chronic obstructive lung disease
- COPD chronic obstructive lung disease
- IRDS infant respiratory distress syndrome
- ARDS acute respiratory distress syndrome
- lung infections persistent pulmonary hypertension, lung hypoplasia, cancer, cystic fibrosis, alveolar proteinosis, upper respiratory inflammation, congenital SP-B deficiency, respiratory syncytial virus (RSV), allergic rhinitis, and/or influenza.
- the present invention further provides a method of treatment of a disease, disorder or condition associated with a decreased level of SPD in a person, comprising administering to said person a therapeutically effective amount of the system of the invention as described hereinabove or a pharmaceutical composition thereof.
- the present invention also provides a method for pulmonary delivery of SPD comprising administering to a subject in need thereof a therapeutically effective amount of the system of the invention as described hereinabove or a pharmaceutical composition thereof.
- the controlled release feature of the system allows for a lower frequency of administration thereby causing less inconvenience to the patient.
- the controlled release system/nanoparticle of the invention or the pharmaceutical composition comprising it can be administered by various pulmonary delivery methods, for example, by inhalation, nebulization, intratracheal administration such as by intratracheal injection, or a nasal spray.
- dosing can be of a single or a plurality of administrations or a single administration of a slow release composition, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
- compositions to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
- poly lactic-co-glycolic acid (PLGA) 7A MW 96 kDa with an inherent viscosity of 0.63 dl/g
- 50:50 PLGA 1A MW 5.6 kDa with an inherent viscosity of 0.11 dl/g
- Polyvinyl alcohol (PVA, MW 85-124 kDa; 87-89% hydrolyzed, 9002-89-5) Ethyl acetate (34848) and Sodium Hydroxide (1310-73-2) were obtained from Sigma-Aldrich Inc.
- SPD Surfactant protein D
- SPD Surfactant protein D protein was synthesized in Cincinnati Children's Hospital Medical Center (CCHC) by methods as described in Ikegami et al.
- Micro BCATM protein assay (23235) was purchased from ORNAT, Biochemicals & Laboratory Equipment Ltd. Thiazolyl Blue Tetra-zolium Bromide (MTT) (M2128) was purchased from Sigma-Aldrich Inc. Hydrochloric acid 32% (08460201), was purchased from Bio-Lab.
- DMEM high glucose medium (01-055-1A)
- Fetal Bovine Serum (FBS)
- FBS Fetal Bovine Serum
- EDTA Trypsin Ethylene diamine tetra acetic acid
- L-glutamine (03-020-1B
- Penicillin-streptomycin (03-031-1B) were purchased from Biological Industries Beit Haemek.
- SPD surfactant protein D
- Q-Sonica 700 W, 20 KHz, 35% amplitude
- PVA polyvinyl alcohol
- the resulting nano-sized particles were stirred in solution for 3 h to allow for ethyl acetate evaporation.
- the NPs were centrifuged, washed 3 times with DDW, and finally resuspended in 4 ml DDW and dried in a lyophilizer.
- the surface morphology and shape of the nanoparticles were investigated by scanning electron microscopy (HRSEM, JSM-7400F). To this end, approximately one drop of nanoparticles suspension was mounted on an aluminum stub and sputter coated for 30 s with a thin layer of gold under vacuum and then observed with a scanning electron microscope operating at 3 kV and 20 ° C.
- the surface charge of the NPs was determined by Zeta potential. Samples from DLS were transferred to U-tube cuvette (DTS1060C, Malvern) for subsequent zeta potential measurements using Zetasizer (ZN-NanoSizer, Malvern, England). SPD—loaded and empty PLGA 1A and 7A NPs were measured at automatic mode, at 25° C., and the Smoluchowski model was used to calculate the zeta potential. For each sample the zeta potential value was presented as the average value of three runs.
- BALF Bronchiolar Lavage Fluid
- 7.5 mg of SPD-loaded NPs were mixed with 150 ul PBS, spun for 5 minutes at 800 RPM to wash. Wash process was repeated and fresh PBS placed on bead after second wash. Tubes containing particles were rotated at room temp and samples were collected daily for 1 week, stored at ⁇ 20° C. and analyzed by silver stain gel according to standard procedures.
- MTT stock solution was prepared by dissolving 5 mg of MTT powder in 1 mL of filter sterilized PBS. The cell medium was replaced with 0.5 mL of fresh starvation medium and 50 ⁇ L of MTT solution was added to each well. Cells were incubated for 4 hours in the incubator after which 1 mL of MTT solvent, dimethylsulfoxide (DMSO), was added to each well. The cell plates were incubated over night at room temperature in a sterile hood. Absorbance of each well was read at wavelength of 570 nm and reference of blank solution (MTT+DMEM medium+DMSO) was used. Cell viability was calculated by equation 1:
- Cell viability (%) Optical density (OD) of the treated cells/OD of the non-treated cells ⁇ 100% (1)
- the remaining HRP conjugate is allowed to react with 100 ⁇ l Substrate Solution (TMB) that was added to each well.
- TMB Substrate Solution
- the microplate was incubated for 15 min after covering the plate with aluminum foil.
- the reaction was stopped by addition of 100 ⁇ l acidic solution and absorbance of the resulting yellow product was measured at 450 nm wavelength. The absorbance is proportional to the concentration of surfactant protein D.
- nanoparticles were observed by Scanning Electron Microscope.
- the SPD-loaded PLGA NPs were spherical and had a smooth surface without pores or cavities which could affect the release of the encapsulated protein.
- the PLGA 1A NP size was not homogeneous compared to PLGA 7A NPs. In both types of PLGA there was no difference in shape between the NPs with protein and the empty NPs
- NPs including SPD showed a highly negative Zeta potential ( ⁇ 35 mV).
- the pl value of SPD is 5-8 according to the literature.
- the large value of the zeta potential is predictive of high colloidal stability.
- the number of macrophage and neutrophils was similar to the number in the control group indicating that the PLGA NPs were not toxic to the mice.
- SPD surfactant protein-D
- NPs NPs have toxic effect
- MTT assay 0.5 ml of A549 Lung cells were seeded in a 24 well plate at a density of 30,000 cells/well in DMEM growth medium and incubated at 37° C. and 5% CO 2 for 24 hours to promote cell attachment. Following incubation, the culture medium was removed, and the samples were washed twice with 0.5 ml phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- PLGA 7A NPs with SP-D, as well as empty NPs for negative control were dissolved in DMEM starvation medium (containing 1% L-glutamine, 1% penicillin-streptomycin, and 5% FBS) to final NPs concentration of 0.5 mg/ml or 1 mg/ml and incubated at 37° C. for 24 hr. Untreated A549 cells were used as the control. Following 24 hr incubation, a standard MTT assay was performed according to manufacturer's procedure. The samples were taken in triplicate.
- Example 8 Short Term Experiment—Acute Inflammatory Response
- mice were subjected to bronchiolar lavage using 1 ml of PBS that was injected to the trachea.
- Bronchiolar Lavage Fluid (BALF) was collected, spun at 4000 ⁇ g for 10 minutes and the remaining supernatant was tested for IL-6, a cytokine that drives acute inflammatory response thus can be an inflammation marker, using ELISA according to manufacture procedure.
- BALF Bronchiolar Lavage Fluid
- IL-6 is a plleiotropic, ⁇ -helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 drives the acute inflammatory response and it is almost solely responsible for fever. It is important in the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (C. Garbers, H. M. Hermanns, F. Schaper, G. Muller-Newen, J. Grotzinger, S.
- IL-6 concentration in the lungs of mice treated with NPs was 3.2 pg/ml, similar to the level in untreated mice (2.7 pg/ml), indicating that no short term inflammation was observed as a result from PLGA 7A NPs treatment on mice by using tracheal injection.
- mice In order to determine whether SP-D will be released from the NPs in the lungs, wild-type mice were injected intratracheally with SP-D loaded PLGA 7 A NPs dissolved in PBS (2 mg/ml) at two different doses of 5 or 20 ⁇ g NPs per gram of body weight, to assess which dose will release the proper amount of SP-D.
- the control group was untreated mice. After Two days, 1 ml of Bronchiolar Lavage Fluid (BALF) was collected from the mice and centrifuge for 5 min at 10,000 RPM at temperature of 4° C. The resulting supernatant was assayed by human-SP-D ELISA, according to manufacture procedure, for SP-D concentration determination.
- BALF Bronchiolar Lavage Fluid
- SP-D knock-out mice (disclosed in WO 00/23569) were treated with 20 ⁇ g NPs per gram body weight of SP-D loaded PLGA 7A NPs by an intra-tracheal injection.
- the control groups were mice treated with empty PLGA 7A NPs or untreated. After 3 and 7 days, the amount of SP-D that was released from the NPs was determined using SP-D ELISA.
- SP-D was released from NPs after 3 days but after 7 days there was no SP-D in the lungs.
- the SP-D concentration extracted from the lungs fluids was lower than the concentration in the wild-type mice experiment described above.
- Example 11 Decrease in Inflammation Following a Lung Injury Caused by Infection or Hyperoxia
- Lung injury is inflicted in wild-type or SPD knock-out mice by intratracheal or intranasal administration of bacteria, bacterial products such as LPS, virus or fungi; or by induction of hyperoxia for example by exposing the mice to >95% O 2 for 72 hrs.
- Injured mice are treated with an appropriate dose of PLGA 7A NPs complexed with human SPD by an intratracheal injection.
- the control group is injured mice treated with empty PLGA 7A NPs.
- lung lavage is evaluated for human SPD content by spinning 600 ⁇ l for 5 min at 10,000 RPM at 4° C. and assaying by SPD ELISA, and the extent of inflammation is assessed, for example by following neutrophilic alveolitis, indicating the presence of an inflammatory response in the alveoli.
Abstract
Description
- The present invention relates to a controlled release system for administration of surfactant protein D for treating lung disease.
- Preterm infants, particularly those of very low birth weight that were born between week 23 and week 28 of gestation, suffer from a very high incidence of respiratory distress syndrome (RDS) related to pulmonary immaturity and inability to make pulmonary surfactant lipids and proteins. These infants are supported by the use of oxygen, ventilators, and routine administration of surfactant replacement. The surfactant replacement preparations currently at use contain surfactant protein (SP) B and SPC but do not contain SPA, SPD, or other innate host-defense proteins (Ikegami et al. 2006; WO 90/11768). SPD is a hydrophilic surfactant protein that decreases pulmonary inflammation and facilitates normal surfactant lipid structure and recycling. Its use as a surfactant replacement has been described (Legami et al. 2006;
WO 07/056195; WO 02/17878;WO 00/023569; US 2011/0189104; U.S. Pat. No. 7,266,403) but never implemented commercially, possibly due to problems associated with consistent delivery of large oligomerized proteins such as SPD. Furthermore, since repeated intubation or instillation into the airway is challenging in small infants, a sustained release vehicle that provides surfactant replacement, including SPD, for long periods of time in lungs of preterm infants would be highly desirable, but there is currently no system or device for sustained release of SPD in the alveoli of infants or adults. - According to one aspect, the present invention provides a controlled release system comprising surfactant protein D (SPD) and a carrier suitable for controlled release.
- According to another aspect, the present invention provides a nanoparticle comprising SPD and PLGA.
- According to an additional aspect, the present invention provides a pharmaceutical composition comprising the controlled release system or nanoparticle according to the invention.
- According to yet another aspect, the present invention provides a method of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, comprising administering the system or nanoparticle according to the invention or a pharmaceutical composition thereof to said subject.
- According to still another aspect, the present invention provides a method for pulmonary delivery of SPD comprising administering to a subject in need thereof the system or nanoparticle according to the invention or a pharmaceutical composition thereof.
-
FIGS. 1A-1D show scanning Electron Microscopy (SEM) images of poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) with surfactant protein D (SPD).FIGS. 1A and 1B :PLGA 1A NPs with SPD;FIGS. 1C and 1D :PLGA 7A NPs with SPD.FIGS. 1A and 1C are at ×10,000 magnification, andFIGS. 1B and 1D are at ×35,000 magnification. -
FIG. 2 shows hydrodynamic radius of PLGA NPs with SPD in PBS solution measured with Dynamic Light Scattering (DLS). From left to right: PLGA-7A, PLGA-7A with SPD, PLGA-1A, PLGA-1A with SPD. -
FIG. 3 shows size distribution ofPLGA 7A NPs with SPD measured with Dynamic Light Scattering (DLS) (n=3). -
FIG. 4 shows Zeta potential ofPLGA -
FIG. 5 shows toxicity test of C57b1/6 mice by intra-tracheal injection ofPLGA 7A empty NPs at 10 and 20 μg particles per gram body weight, 2 or 4 weeks after the 8injection. Control group was injected with 100 μl sterile PBS and tested after 2 weeks. Each group: Macrophages: (left black bars), neutrophils: (right gray bars). -
FIG. 6 shows SDS-PAGE analysis of SPD released from NPs during one week. First four lanes from the left include different concentrations of SPD (left to right: 25, 50, 100 and 200 μg/ml), next two lanes include washes, and the following lanes include daily samples fromday 0 today 7. The right-most lane is sample taken atday 1 without β-ME (normally added to each sample to keep a denatured state). 40 kD marks the approximate location of the SPD monomer (43 kDa), and 120 kD marks the approximate location of the SPD trimer (129 kDa). -
FIG. 7 shows biological activity of SPD protein that was released fromPLGA 1A NPs during one week using bacterial aggregation assay. PBS: blue diamond, wash: red square. Day 0: green triangle, Day 1: purple X, Day 2: blue asterisk, Day 3: orange circle, Day 4: perpendicular bar, Day 5: brown line, Day 6: green line, Day 7: purple diamond. -
FIG. 8 shows short term toxicity test of C57bl/6 mice after intra-tracheal injection withPLGA 7A NPs at 10 μg particles per g body weight (left bar). Control group was injected with PBS (n=4, right bar). IL-6 concentration in Bronchiolar Lavage Fluid (BALF) was detected using ELISA. -
FIG. 9 shows SP-D concentration, measured by human SP-D ELISA, in bronchial lung lavage supernatant from wild-type mice after intra-tracheal injection of 5 (left bar), 10 (middle bar) or 20 (third bar from left) μg/g body weight (gbw) ofPLGA 7A NPs with SP-D. Control group were untreated mice, (n=3) (right bar). -
FIG. 10 shows SP-D concentration measured by human SP-D ELISA, in bronchial lung lavage supernatant from knock-out mice after intra-tracheal injection ofPLGA 7A NPs with SP-D at 20 μg per gram body weight (left bars), or ofempty PLGA 7A NPs (middle bars). Control group was untreated mice, (n=3) (right bar). Each group: left bar (dark)—measured after 3 days, right bar (light)—measured after 7 days. - In the present application, the inventors have found that poly lactic-co-glycolic acid (PLGA) can form nanoparticles with surfactant protein D (SPD). Importantly, it was found that the SPD protein is released from the nanoparticles and maintains its biological activity, and therefore a system comprising PLGA and SPD can be used as a carrier in a delivery system for controlled release of SPD in the lungs.
- Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible FDA-approved copolymer used as a vehicle for delivery, including controlled delivery of drugs. PLGA is synthesized by means of ring-opening co-polymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid. Polymers can be synthesized as either random or block copolymers thereby imparting additional polymer properties. During polymerization, successive monomeric units (of glycolic or lactic acid) are linked together in PLGA by ester linkages, thus yielding linear, aliphatic polyester as a product. Depending on the ratio of lactide to glycolide used for the polymerization, different forms of PLGA can be obtained: these are usually identified in regard to the molar ratio of the monomers used (e.g. PLGA 75:25 identifies a copolymer whose composition is 75% lactic acid and 25% glycolic acid).
- Additional carriers may be used in accordance with the present invention instead of PLGA, including polymeric carriers such as polylactic acid (PLA), polyglycolic acid (PGA), chitosan, gelatin, polycaprolactone and poly-alkyl-cyanoacrylates (Kumari et al, 2010). In some embodiments the carrier is biodegradable.
- Examples 1-3 show that PLGA and SPD form complexes having the size of nanoparticles. Example 5 further demonstrates that SPD protein continues to he released from these nanoparticles for a duration of at least a week, and Example 6 shows that the released SPD is biologically active. Examples 9 and 10 show that SPD is released from the SPD NPs of the invention after administration to lungs of wild-type or knock-out mice.
- Accordingly, the present invention provides a controlled release system comprising SPD and a carrier suitable for controlled release.
- According to some embodiments, the carrier of the system/nanoparticle is polymeric, i.e. comprising a polymer. In some embodiments the carrier is PLGA.
- The term “complex” as used herein refers to a molecular entity formed by loose association involving two or more component molecular entities (ionic or uncharged), or the corresponding chemical species; and this term and the term “system” are used herein interchangeably.
- The ratio of lactic acid to glycolic acid in the PLGA polymer of the system/nanoparticle may vary. The ratio which was used in the experiments of the present invention is 50:50. However, other ratios may also be suitable as indicated below.
- Accordingly, in some embodiments, the ratio of lactic acid to glycolic acid in said PLGA is 50:50, 65:35, 70:30, 75:25, 82:18 or 85:15, in particular the ratio is 50:50.
- The polymer may be at any of various inherent viscosities between 0.05 and 7.0 dL/g, for example 0.05 to 1 dl/g or between 0.1 to 0.7 dl/g (depending on the molecular weight, molecular weight distribution, and consistency of the polymer). The molecular weight of the PLGA may be selected from between 1 to 200, between 3 to 150 or between 5 to 100 kDa. In the examples presented hereinbelow, two types of PLGA polymers were used, with molecular weights of 96 kDa and (inherent viscosity of 0.63 dl/g) and 5.6 kDa (and inherent viscosity of 0.11 dl/g).
- From Example 2 it can be seen that the radius of the nanoparticles is about 100 nm. Accordingly, in some embodiments, the system is a nanoparticle or a microparticle, in particular a nanoparticle. In some embodiments, the average radius of said nanoparticle is selected from between 20 and 300, between 50 and 150 nm, or about 100 nm.
- The zeta potential affects the tendency of the particles to aggregate; charged particles have a lesser tendency to aggregate due to the repulsing forces of particles having the same charge, while neutrally charged particles have a tendency to aggregate. There is therefore an advantage to particles having a charge. The SPD-loaded PLGA nanoparticles disclosed in herein have a negative zeta potential of about −35 mV (Example 3).
- In some embodiments the present invention provides a nanoparticle comprising SPD and PLGA.
- SPD was prepared as previously described (Ikegami et al., 2006). In some embodiments, the SPD may be recombinant SPD. In some embodiments, the SPD is a mammalian SPD, in particular human SPD.
- In some embodiments, the system does not contain surfactant components other than SPD. For example, the system comprises SPD but is void of SPA, SPB or SPC.
- The system/nanoparticle of the present invention is prepared by standard methods used in the art such as the double emulsion evaporation technique, emulsification-solvent evaporation technique, or the nanoprecipitation method also called the interfacial deposition method (Danhier et al, 2012).
- The term “controlled release” is used herein interchangeably with the terms “prolonged-action”, “repeat-action”, “extended release”, and “sustained-release” and refers to the release of an active agent at predetermined intervals or gradually, in such a manner as to make the contained active agent available over an extended period of time
- In some embodiments, the system of the invention as described hereinabove is for use in pulmonary delivery of SPD, i.e. for use in delivery of SPD to the lungs.
- The present invention also provides a pharmaceutical composition comprising the system/complex/nanoparticle of the invention as described hereinabove and a pharmaceutically acceptable carrier.
- Methodology and components for formulation of pharmaceutical compositions are well known and can be found, for example, in Remington's Pharmaceutical Sciences, Eighteenth Edition, A. R. Gennaro, Ed., Mack Publishing Co. Easton Pa., 1990. Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active agents into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- The pharmaceutical composition may be aerosolized by any known method such as by a pneumatic, jet or ultrasonic nebulizer. Methods and devices for aerosolization are described, for example, in Labiris and Dolovich 2003, Br. J. Clin. Pharmacol. 56: 600-612, and in Ibrahim et al., 2015, Medical Devices: Evidence and Research 8: 131-139.
- In some embodiments, the pharmaceutical composition is in the form of an aerosol, spray or mist.
- The term “pharmaceutically acceptable carrier” refers to a vehicle which delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms. As used herein, “pharmaceutical” will be understood to encompass both human and veterinary pharmaceuticals. Useful carriers include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1, 3-diol, isopropyl myristate, isopropyl palmitate, mineral oil and polymers composed of chemical substances like polyglycolic acid or polyhydroxybutyrate or natural polymers like collagen, fibrin or polysaccharides like chitosan and alginate. The carrier may be in any form appropriate to the mode of delivery, for example, solutions, colloidal dispersions, emulsions (oil-in-water or water-in-oil), suspensions, gels, sprays and the like.
- Several human lung diseases are characterized by decreased levels of bronchoalveolar SPD and may therefore be treated by administration of the system of the present invention.
- The term “decreased levels of bronchoalveolar SPD” as used herein refers to partial or complete deficiency of bronchoalveolar SPD as compared with the level of bronchoalveolar SPD in normal healthy individual(s). It has been shown for several diseases, including acute respiratory distress syndrome (ARDS) and respiratory syncytial virus (RSV) that the levels of SPD, even if they are within the normal range, correlate with mortality rates or with disease outcome. Accordingly, the term “decreased levels of bronchoalveolar SPD” may be also used to further refer to a decreased level of bronchoalveolar SPD which is still within the normal range but is associated with poor prognosis of a disease.
- Non-limiting examples of individuals having decreased levels of bronchoalveolar SPD, i.e. individuals in need for treatment, include preterm infants, particularly those of very low birth weight that were born between about week 23 and about week 28 of gestation, and individuals with a mutated spd gene resulting in reduced expression or altered activity.
- Thus, in some embodiments, the system/nanoparticle or the pharmaceutical composition of the invention as described hereinabove is for use in the treatment of a disease, disorder or condition associated with a decreased level of a SPD.
- In some embodiments, the disease, disorder or condition is selected from chronic obstructive lung disease (COPD), asthma, acute bronchitis, chronic bronchitis, bronchopulmonary dysplasia, emphysema, infant respiratory distress syndrome (IRDS), acute respiratory distress syndrome (ARDS), lung infections, persistent pulmonary hypertension, lung hypoplasia, cancer, cystic fibrosis, alveolar proteinosis, upper respiratory inflammation, congenital SP-B deficiency, respiratory syncytial virus (RSV), allergic rhinitis, and/or influenza. In some embodiments, the disease, disorder or condition is selected from IRDS, cystic fibrosis, and emphysema.
- The present invention further provides a method of treatment of a disease, disorder or condition associated with a decreased level of SPD in a person, comprising administering to said person a therapeutically effective amount of the system of the invention as described hereinabove or a pharmaceutical composition thereof.
- The present invention also provides a method for pulmonary delivery of SPD comprising administering to a subject in need thereof a therapeutically effective amount of the system of the invention as described hereinabove or a pharmaceutical composition thereof.
- As explained above, the controlled release feature of the system allows for a lower frequency of administration thereby causing less inconvenience to the patient.
- The term “treating” or “treatment” as used herein includes alleviating, abrogating, substantially inhibiting, slowing, reducing or reversing the progression of a condition, substantially ameliorating or reducing clinical symptoms of a condition, substantially preventing the appearance of clinical symptoms of a condition, or complete cure of the disease.
- The controlled release system/nanoparticle of the invention or the pharmaceutical composition comprising it can be administered by various pulmonary delivery methods, for example, by inhalation, nebulization, intratracheal administration such as by intratracheal injection, or a nasal spray.
- Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a “therapeutically effective amount” means an amount of an active ingredient effective to prevent, alleviate or ameliorate symptoms of a disease or disorder or prolong the survival of the subject being treated.
- Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- Depending on the severity and responsiveness of the condition to he treated, dosing can be of a single or a plurality of administrations or a single administration of a slow release composition, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
- The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
- The term “about” as used herein means that values of 10% or less above or below the indicated values are also included.
- The invention will now be illustrated in the following non-limiting examples.
- 50:50 poly lactic-co-glycolic acid (PLGA) 7A, MW 96 kDa with an inherent viscosity of 0.63 dl/g and 50:50
PLGA 1A, MW 5.6 kDa with an inherent viscosity of 0.11 dl/g were purchased from Lakeshore Biomaterials. Polyvinyl alcohol (PVA, MW 85-124 kDa; 87-89% hydrolyzed, 9002-89-5), Ethyl acetate (34848) and Sodium Hydroxide (1310-73-2) were obtained from Sigma-Aldrich Inc. Surfactant protein D (SPD) protein was synthesized in Cincinnati Children's Hospital Medical Center (CCHC) by methods as described in Ikegami et al. 2006. Micro BCA™ protein assay (23235) was purchased from ORNAT, Biochemicals & Laboratory Equipment Ltd. Thiazolyl Blue Tetra-zolium Bromide (MTT) (M2128) was purchased from Sigma-Aldrich Inc. Hydrochloric acid 32% (08460201), was purchased from Bio-Lab. DMEM high glucose medium (01-055-1A), Fetal Bovine Serum (FBS) (04-121-1A), Trypsin Ethylene diamine tetra acetic acid (EDTA) (03-052-1B), L-glutamine (03-020-1B), Penicillin-streptomycin (03-031-1B) were purchased from Biological Industries Beit Haemek. - Two types of PLGA 50:50 with different molecular weights (
PLGA 7A-96 kDa andPLGA 1A-5.6 kDa) were used to prepare PLGA nanoparticles (NPs) using a double emulsion evaporation technique (w/o/w=water/oil/water). 100 mg PLGA were dissolved in 2 ml of ethyl acetate solvent in a glass tube. 2.5 mg of surfactant protein D (SPD) were dissolved in 100 μL DDW and then added to the polymer/solvent mixture and emulsified by sonication (Q-Sonica, 700 W, 20 KHz, 35% amplitude) for 10 s in an ice bath to form a primary emulsion. The solution was then added at a high setting vortex to 4 ml of an external aqueous phase, containing 5% w/v PVA (polyvinyl alcohol) as a stabilizer. The contents were sonicated 3 times for 10 s (35% amplitude). The resulting solution was then added drop wise into 50 ml of a 0.5% w/v aqueous PVA solution under magnetic stirring. The resulting nano-sized particles were stirred in solution for 3 h to allow for ethyl acetate evaporation. The NPs were centrifuged, washed 3 times with DDW, and finally resuspended in 4 ml DDW and dried in a lyophilizer. - Mean particle size and size distribution of the SPD- loaded and
empty PLGA - The surface morphology and shape of the nanoparticles were investigated by scanning electron microscopy (HRSEM, JSM-7400F). To this end, approximately one drop of nanoparticles suspension was mounted on an aluminum stub and sputter coated for 30 s with a thin layer of gold under vacuum and then observed with a scanning electron microscope operating at 3 kV and 20 ° C.
- The surface charge of the NPs was determined by Zeta potential. Samples from DLS were transferred to U-tube cuvette (DTS1060C, Malvern) for subsequent zeta potential measurements using Zetasizer (ZN-NanoSizer, Malvern, England). SPD—loaded and
empty PLGA - To determine if treatment with nanoparticles induces a chronic inflammatory response by looking primarily at macrophage and neutrophils in Bronchiolar Lavage Fluid (BALF), mice were treated with either 10 μg/g body weight (n=10), 20 μg/g body weight PLGA nanoparticles (n=4), or PBS for controls (n=5). 2 and 4 weeks after tracheal injection subsets of mice were lavaged and some had lungs inflation fixed for histology. BALF was spun at 4000×g for 10 minutes and pelleted cells resuspended in 150 ul PBS. 140 ul of suspension was used for Cytospin, 5 minutes at 500 RPM. Slides were allowed to dry and H&E stain was performed and cells were counted.
- 7.5 mg of SPD-loaded NPs were mixed with 150 ul PBS, spun for 5 minutes at 800 RPM to wash. Wash process was repeated and fresh PBS placed on bead after second wash. Tubes containing particles were rotated at room temp and samples were collected daily for 1 week, stored at −20° C. and analyzed by silver stain gel according to standard procedures.
- The biological activity of SPD released from NPs was analyzed using Bacterial Aggregation Assay (Hartshorn et al. 1998, Am. J. Physiol.—Lung Cellular and Molecular Physiology 274(6):L958-L969). E. coli Y1088 cultures were spun down, media removed, and washed in 1× TBS (Tris-buffered saline). Bacteria was spun down again and resuspended in Hank's Balanced Salt Solution (HBSS) such that the absorbance reading at A700 is 1. Samples are loaded into Beckman DU 640 spectrophotometer cuvette containing 5 mM CaCl2 , E. coli, and SPD (5 ul of eluate per elution day tested) and A700 readings are taken every 2.5 minutes using a kinetics program. Control sample with PBS was also run for comparison.
- MTT stock solution was prepared by dissolving 5 mg of MTT powder in 1 mL of filter sterilized PBS. The cell medium was replaced with 0.5 mL of fresh starvation medium and 50 μL of MTT solution was added to each well. Cells were incubated for 4 hours in the incubator after which 1 mL of MTT solvent, dimethylsulfoxide (DMSO), was added to each well. The cell plates were incubated over night at room temperature in a sterile hood. Absorbance of each well was read at wavelength of 570 nm and reference of blank solution (MTT+DMEM medium+DMSO) was used. Cell viability was calculated by equation 1:
-
Cell viability (%)=Optical density (OD) of the treated cells/OD of the non-treated cells×100% (1) - In Human Surfactant Protein D ELISA, standards and samples were incubated in microplate wells pre-coated with monoclonal anti-human surfactant protein D antibody. 100 μl of standard and sample were added to the microplate wells and incubate for 2 hour at room temperature on an orbital shaker at 300 rpm. After incubation, the wells were washed 5 times. 100 μl of Biotin labelled monoclonal anti-human SP-D antibody was added into each well and incubated with the captured SP-D for 60 minutes on an orbital shaker at 300 rpm. After another washing (5 times), 100 μl of Streptavidin-HRP Conjugate was added and shaken for 60 minutes. After incubation and the last washing step, the remaining HRP conjugate is allowed to react with 100 μl Substrate Solution (TMB) that was added to each well. The microplate was incubated for 15 min after covering the plate with aluminum foil. The reaction was stopped by addition of 100 μl acidic solution and absorbance of the resulting yellow product was measured at 450 nm wavelength. The absorbance is proportional to the concentration of surfactant protein D.
- In order to investigate the physicochemical characterization of nanoparticles prepared by the double emulsion method, nanoparticles were observed by Scanning Electron Microscope. As shown in
FIGS. 1A-1D , the SPD-loaded PLGA NPs were spherical and had a smooth surface without pores or cavities which could affect the release of the encapsulated protein. ThePLGA 1A NP size was not homogeneous compared toPLGA 7A NPs. In both types of PLGA there was no difference in shape between the NPs with protein and the empty NPs - The DLS method was used in order to determine the mean size and size distribution of the NPs. DLS can calculate the hydrodynamic diameter of a particle from Stokes-Einstein equation by measuring the scattered light of the particles that are moving in Brownian motion. PLGA-
NPs FIG. 2 ). The size distribution of nanoparticles is shown inFIG. 3 .PLGA 1A with SPD showed two populations of particles on DLS and the SEM results. One population demonstrated particles with hydrodynamic radius of around 100 nm, similar to empty NPs, and an additional population with radius of around 600 nm. For further experiments or treatment the population including the larger particles was removed by filtration before using the NPs. - Zeta potential measures the surface charge of particles and can give indication of the tendency of the particle suspension to aggregate and sediment.
FIG. 4 shows the Zeta potential ofPLGA 1A without SPD andPLGA 7A with and without SPD. The low values indicate that the charge of the empty NPs is 0 and the particles aggregate as can be observed from the SEM images. - NPs including SPD showed a highly negative Zeta potential (−35 mV). The pl value of SPD is 5-8 according to the literature. The large value of the zeta potential is predictive of high colloidal stability.
-
FIG. 5 presents a toxicity test of C57bl/6 mice intra-tracheal injection withPLGA 7A NPs at 10 or 20 μg particles per gram of body weight. The control group is a solution with 100 μl sterile PBS. In this test the number of macrophage and neutrophils recovered was compared to the control group and tested after 2 and 4 weeks. - As we can see in
FIG. 5 , the number of macrophage and neutrophils was similar to the number in the control group indicating that the PLGA NPs were not toxic to the mice. - Samples of surfactant protein-D (SPD) that were released from PLGA NPs during one week were analyzed every day using silver stain gel. As we can see in
FIG. 6 , SPD keeps being released from nanoparticles for a duration of at least one week and the integrity of the protein was also maintained during the encapsulation process. - To determine if the SPD released from nanoparticles is biologically active a bacterial aggregation assay was performed. The decreasing absorbance in
FIG. 7 shows that SPD eluted from nanoparticles is biologically active, with activity slowly decreasing aroundday 2 and rapidly deteriorating byday 6. Though activity decreases over time, nanoparticles do release biologically active SPD protein for several days. - In order to investigate whether the NPs have toxic effect, cell viability was assessed using the MTT assay. 0.5 ml of A549 Lung cells were seeded in a 24 well plate at a density of 30,000 cells/well in DMEM growth medium and incubated at 37° C. and 5% CO2 for 24 hours to promote cell attachment. Following incubation, the culture medium was removed, and the samples were washed twice with 0.5 ml phosphate buffered saline (PBS).
PLGA 7A NPs with SP-D, as well as empty NPs for negative control, were dissolved in DMEM starvation medium (containing 1% L-glutamine, 1% penicillin-streptomycin, and 5% FBS) to final NPs concentration of 0.5 mg/ml or 1 mg/ml and incubated at 37° C. for 24 hr. Untreated A549 cells were used as the control. Following 24 hr incubation, a standard MTT assay was performed according to manufacturer's procedure. The samples were taken in triplicate. - Treatment with 0.5 mg/ml of
PLGA 7A NPs showed around 80% cell viability and treatment with 1 mg/ml ofPLGA 7A NPs showed cell viability values of about 70% (data not shown). The viability of the cells with empty NPs was about 80-90%. Although the concentration of NPs influences the cell viability, these high values indicate that the NPs are not toxic to the cells for both concentrations. - In order to determine whether NP administration induces an acute inflammatory response, C57B16 mice were treated with 10 mg per gram body weight of
PLGA 7A NPs (2.0 mg/ml in PBS, n=4) or PBS for controls (n=4) given via tracheal injection. Six hours after injection, mice were subjected to bronchiolar lavage using 1 ml of PBS that was injected to the trachea. Bronchiolar Lavage Fluid (BALF) was collected, spun at 4000×g for 10 minutes and the remaining supernatant was tested for IL-6, a cytokine that drives acute inflammatory response thus can be an inflammation marker, using ELISA according to manufacture procedure. - The purpose of the In vivo toxicity test was to determine if treatment with empty PLGA NPs induces inflammatory response in mice before conducting in vivo experiments with SP-D loaded NPs. IL-6 is a plleiotropic, α-helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 drives the acute inflammatory response and it is almost solely responsible for fever. It is important in the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (C. Garbers, H. M. Hermanns, F. Schaper, G. Muller-Newen, J. Grotzinger, S. Rose-John, J. Scheller, Plasticity and cross-talk of interleukin 6-type cytokines, Cytokine Growth Factor Rev. 23 (2012) 85-97). As can be seen from
FIG. 8 , IL-6 concentration in the lungs of mice treated with NPs was 3.2 pg/ml, similar to the level in untreated mice (2.7 pg/ml), indicating that no short term inflammation was observed as a result fromPLGA 7A NPs treatment on mice by using tracheal injection. - In order to determine whether SP-D will be released from the NPs in the lungs, wild-type mice were injected intratracheally with SP-D loaded
PLGA 7A NPs dissolved in PBS (2 mg/ml) at two different doses of 5 or 20 μg NPs per gram of body weight, to assess which dose will release the proper amount of SP-D. The control group was untreated mice. After Two days, 1 ml of Bronchiolar Lavage Fluid (BALF) was collected from the mice and centrifuge for 5 min at 10,000 RPM at temperature of 4° C. The resulting supernatant was assayed by human-SP-D ELISA, according to manufacture procedure, for SP-D concentration determination. - As can he observed in
FIG. 9 , for 1 ml BALF that was collected from the mice, negligible amount of SP-D was released from 5 and 10 μg/g body weight, while 239 ng of SP-D was released from 20 μg/g body weight. Since the ELISA is specific for human SP-D, as expected no SP-D was detected in the untreated mice control group. This finding emphasizes the fact that the SP-D that was found by using the ELISA is SP-D that was released from NPs only. The 239 ng SP-D that was released from 20 μg/g body weight of NPs fits to the preferred amount of SP-D needed in lungs of mice (100-300 ng), thus this dose was applied for further experiments with SP-D knock-out mice. - After determination of the appropriate dose based on the wild-type mice experiment above, SP-D knock-out mice (disclosed in WO 00/23569) were treated with 20 μg NPs per gram body weight of SP-D loaded
PLGA 7A NPs by an intra-tracheal injection. The control groups were mice treated withempty PLGA 7A NPs or untreated. After 3 and 7 days, the amount of SP-D that was released from the NPs was determined using SP-D ELISA. - As shown in
FIG. 10 , SP-D was released from NPs after 3 days but after 7 days there was no SP-D in the lungs. Moreover, the SP-D concentration extracted from the lungs fluids was lower than the concentration in the wild-type mice experiment described above. One explanation could be that for knock-out mice, more SP-D was consumed than in the wild type mice, which have SP-D naturally, and therefore the concentration was lower. It can be that changes in the experiment such as larger dose of NPs to be delivered will release appropriate amount of SP-D for one week. - Lung injury is inflicted in wild-type or SPD knock-out mice by intratracheal or intranasal administration of bacteria, bacterial products such as LPS, virus or fungi; or by induction of hyperoxia for example by exposing the mice to >95% O2 for 72 hrs. Injured mice are treated with an appropriate dose of
PLGA 7A NPs complexed with human SPD by an intratracheal injection. The control group is injured mice treated withempty PLGA 7A NPs. After an appropriate time, for example when the control group exhibits significant signs of injury, lung lavage is evaluated for human SPD content by spinning 600 μl for 5 min at 10,000 RPM at 4° C. and assaying by SPD ELISA, and the extent of inflammation is assessed, for example by following neutrophilic alveolitis, indicating the presence of an inflammatory response in the alveoli. - To demonstrate treatment of emphysema and pulmonary infections, clearance of bacteria, virus and fungi from the lung is assessed in treated or un-treated SPD knock-out mice (for example as taught in WO 00/23569).
- Danhier et al, J. Controlled Release, 2012, 161(2):505-522
- Ikegami et al. 2006, Am. J. Respir. Crit. Care Med. 173:1342-1347
- Kumari et al, Colloids and Surfaces B: Biointerfaces (2010) 75:1-18)
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/752,418 US20230108852A1 (en) | 2015-06-09 | 2022-05-24 | Controlled release system for pulmonary delivery of surfactant protein d |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562172881P | 2015-06-09 | 2015-06-09 | |
PCT/IL2016/050606 WO2016199146A1 (en) | 2015-06-09 | 2016-06-09 | A controlled release system for pulmonary delivery of surfactant protein d |
US201715735005A | 2017-12-08 | 2017-12-08 | |
US16/869,071 US20200261547A1 (en) | 2015-06-09 | 2020-05-07 | Controlled release system for pulmonary delivery of surfactant protein d |
US17/752,418 US20230108852A1 (en) | 2015-06-09 | 2022-05-24 | Controlled release system for pulmonary delivery of surfactant protein d |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/869,071 Continuation US20200261547A1 (en) | 2015-06-09 | 2020-05-07 | Controlled release system for pulmonary delivery of surfactant protein d |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230108852A1 true US20230108852A1 (en) | 2023-04-06 |
Family
ID=57503633
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/735,005 Active US10682396B2 (en) | 2015-06-09 | 2016-06-09 | Controlled release system for pulmonary delivery of surfactant protein D |
US16/869,071 Abandoned US20200261547A1 (en) | 2015-06-09 | 2020-05-07 | Controlled release system for pulmonary delivery of surfactant protein d |
US17/752,418 Pending US20230108852A1 (en) | 2015-06-09 | 2022-05-24 | Controlled release system for pulmonary delivery of surfactant protein d |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/735,005 Active US10682396B2 (en) | 2015-06-09 | 2016-06-09 | Controlled release system for pulmonary delivery of surfactant protein D |
US16/869,071 Abandoned US20200261547A1 (en) | 2015-06-09 | 2020-05-07 | Controlled release system for pulmonary delivery of surfactant protein d |
Country Status (2)
Country | Link |
---|---|
US (3) | US10682396B2 (en) |
WO (1) | WO2016199146A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3307322T1 (en) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
JPH04504255A (en) | 1989-03-31 | 1992-07-30 | ジェネンテク,インコーポレイテッド | Treatment of respiratory distress syndrome |
US8933032B2 (en) | 1998-10-20 | 2015-01-13 | Children's Hospital Medical Center | Surfactant protein D for the treatment of disorders associated with lung injury |
WO2000023569A1 (en) | 1998-10-20 | 2000-04-27 | Children's Hospital Medical Center | Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
WO2002017878A1 (en) | 2000-09-01 | 2002-03-07 | Marcus Larsson | Lung surfactant compositions with dynamic swelling behaviour |
US20020130430A1 (en) * | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
AU2006311862B2 (en) * | 2005-11-03 | 2012-07-12 | Children's Hospital Medical Center | Surfactant protein-D for prevention and treatment of lung infections and sepsis |
US20070293449A1 (en) * | 2006-06-20 | 2007-12-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for delivery of double-stranded rna |
-
2016
- 2016-06-09 US US15/735,005 patent/US10682396B2/en active Active
- 2016-06-09 WO PCT/IL2016/050606 patent/WO2016199146A1/en active Application Filing
-
2020
- 2020-05-07 US US16/869,071 patent/US20200261547A1/en not_active Abandoned
-
2022
- 2022-05-24 US US17/752,418 patent/US20230108852A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10682396B2 (en) | 2020-06-16 |
WO2016199146A1 (en) | 2016-12-15 |
US20200261547A1 (en) | 2020-08-20 |
US20180161404A1 (en) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Casciaro et al. | Poly (lactide-co-glycolide) nanoparticles for prolonged therapeutic efficacy of esculentin-1a-derived antimicrobial peptides against Pseudomonas aeruginosa lung infection: in vitro and in vivo studies | |
Patel et al. | Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis | |
Xu et al. | Polyphosphoester microspheres for sustained release of biologically active nerve growth factor | |
US10736943B2 (en) | Silk microspheres for encapsulation and controlled release | |
Podaralla et al. | Influence of formulation factors on the preparation of zein nanoparticles | |
US20140271871A1 (en) | Methods and compositions for treating pulmonary hypertension | |
EP2400957B1 (en) | A controlled release micro-capsule for osteogenic action | |
Cohen et al. | SP-D loaded PLGA nanoparticles as drug delivery system for prevention and treatment of premature infant's lung diseases | |
US20230108852A1 (en) | Controlled release system for pulmonary delivery of surfactant protein d | |
US10588860B2 (en) | Poly(vinyl benzoate) nanoparticles for molecular delivery | |
JP2010059211A (en) | Formulation containing bioactive factor and method for using the same | |
Wichert et al. | Low molecular weight PLA: a suitable polymer for pulmonary administered microparticles? | |
Ong et al. | Nanoparticular and other carriers to deliver lactoferrin for antimicrobial, antibiofilm and bone-regenerating effects: a review | |
JP2016523884A (en) | Lipid nanoparticles for wound healing | |
Jagdale et al. | Bird's eye view on aquasome: Formulation and application | |
Liu et al. | Preparation and characterization of bovine serum albumin nanoparticles modified by Poly-l-lysine functionalized graphene oxide for BMP-2 delivery | |
Sato et al. | Thermosensitive polysaccharide particles for pulmonary drug delivery | |
CN109200292B (en) | Nano complex with effect of treating Alzheimer disease and preparation method and application thereof | |
JPH04507412A (en) | pharmaceutical compounds | |
TWI763991B (en) | Novel ophthalmic gel and its preparation method | |
CN115252640B (en) | Chitosan-N-arginine nanoparticle, and preparation method and application thereof | |
Devrim Gökberk et al. | Design, Optimization, and Characterization of Lysozyme-Loaded Poly (ɛ-Caprolactone) Microparticles for Pulmonary Delivery | |
CN114344268B (en) | Naringin nanoparticle with polyhydroxyethyl methacrylate as carrier, and preparation method and application thereof | |
RU2635472C1 (en) | Method for manufacture of microspheres containing medicinal substances as biologically active substance, enclosed in polymer matrix, using microspheres production by double emulsion method | |
Wu et al. | Colon-targeted piperine–glycyrrhizic acid nanocrystals for ulcerative colitis synergetic therapy via macrophage polarization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CHILDREN'S HOSPITAL MEDICAL CENTER, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KINGMA, PAUL SCOT;WHITSETT, JEFFREY A.;SIGNING DATES FROM 20180528 TO 20180605;REEL/FRAME:060002/0423 Owner name: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD, ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOST, JOSEPH;TRAITEL, TAMAR;GOLDBART, RIKI;AND OTHERS;SIGNING DATES FROM 20180501 TO 20180507;REEL/FRAME:060002/0305 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |